Sorafenib
Author:
Publisher
Springer Berlin Heidelberg
Link
http://link.springer.com/content/pdf/10.1007/978-3-642-01222-8_5.pdf
Reference51 articles.
1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300
2. Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y et al (2007) Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21:439–445
3. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D et al (2005) Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92:1855–1861
4. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–3714
5. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM et al (2006) BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326–334
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis;JGH Open;2023-12
2. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022;ACS Omega;2023-07-26
3. miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia;Cell Death Discovery;2023-07-15
4. Pan-cancer analysis of the prognosis and immunological role of AKAP12: A potential biomarker for resistance to anti-VEGF inhibitors;Frontiers in Genetics;2022-08-30
5. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade;The Journal of Clinical Endocrinology & Metabolism;2022-08-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3